NDAOPHTHALMICSUSPENSION/DROPS
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
4/8 — Partial
TOBRADEX (tobramycin and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1988.
Drug data last refreshed 19h ago
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
Started Apr 2010
122 enrolled
Blepharitis
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Started Oct 2009
357 enrolled
ConjunctivitisKeratitisBlepharitis
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Started Oct 2007
221 enrolled
Ocular Inflammation Associated With Blepharaconjunctivitis
Zylet vs TobraDex in Blepharokeratoconjunctivitis
Started Jan 2007
276 enrolled
Blepharokeratoconjunctivitis
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
Started Dec 2006
0Post-surgical Inflammation
Worked on TOBRADEX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.